These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18467290)

  • 1. Rules of tumor cell development and their application to biomarkers for ovarian cancer.
    McLemore MR; Miaskowski C; Aouizerat BE; Chen LM; Dodd M
    Oncol Nurs Forum; 2008 May; 35(3):403-9. PubMed ID: 18467290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and application of protein biomarkers for ovarian cancer.
    Gagnon A; Ye B
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
    Jurisicova A; Jurisica I; Kislinger T
    Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Growth factors in epithelial ovarian cancer].
    Piccinno R; Puopolo M; Rigault De La Longrais IA; Fracchioli S; Massobrio M; Katsaros D
    Minerva Ginecol; 2002 Feb; 54(1):33-52. PubMed ID: 11828269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early events in ovarian oncogenesis.
    Cvetkovic D
    Reprod Biol Endocrinol; 2003 Oct; 1():68. PubMed ID: 14577833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer.
    Bertenshaw GP; Yip P; Seshaiah P; Zhao J; Chen TH; Wiggins WS; Mapes JP; Mansfield BC
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2872-81. PubMed ID: 18843033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer.
    Gadducci A; Cosio S; Tana R; Genazzani AR
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):12-27. PubMed ID: 18595727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ovarian tumors].
    Nakano R
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():331-6. PubMed ID: 16689329
    [No Abstract]   [Full Text] [Related]  

  • 10. Application of proteomics in ovarian cancer: which sample should be used?
    Cadron I; Van Gorp T; Timmerman D; Amant F; Waelkens E; Vergote I
    Gynecol Oncol; 2009 Dec; 115(3):497-503. PubMed ID: 19811810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.
    Tsuchiya T; Nakahama K; Asakawa Y; Maemura T; Tanaka M; Takeda S; Morita M; Morita I
    Gynecol Endocrinol; 2009 Feb; 25(2):104-9. PubMed ID: 19253105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niche-dependent tumorigenic capacity of malignant ovarian ascites-derived cancer cell subpopulations.
    Katz E; Skorecki K; Tzukerman M
    Clin Cancer Res; 2009 Jan; 15(1):70-80. PubMed ID: 19118034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [P53 and its role in the ovarian surface epithelium. A review].
    Chuaire-Noack L; Sánchez-Corredor MC; Ramírez-Clavijo S
    Invest Clin; 2008 Dec; 49(4):561-93. PubMed ID: 19245174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tumour markers in epithelial ovarian cancer].
    Sparholt MH; Høgdall E; Høgdall CK
    Ugeskr Laeger; 2009 Nov; 171(48):3505-9. PubMed ID: 19944049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CA 125 in epithelial ovarian cancer].
    Mogensen O
    Ugeskr Laeger; 1998 May; 160(22):3236. PubMed ID: 9621807
    [No Abstract]   [Full Text] [Related]  

  • 16. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
    Duncan TJ; Al-Attar A; Rolland P; Scott IV; Deen S; Liu DT; Spendlove I; Durrant LG
    Clin Cancer Res; 2008 May; 14(10):3030-5. PubMed ID: 18483368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor markers and ovarian cancer].
    Trifonov I; Todorova M
    Akush Ginekol (Sofiia); 2002; 41 Suppl 1():7-11. PubMed ID: 12412346
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
    Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
    Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers, regerons, and pathways to lethal cancer.
    Qiao M; Pardee AB
    J Cell Biochem; 2007 Dec; 102(5):1076-86. PubMed ID: 17957698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitroand in vivo.
    Zhang X; Deng HX; Zhao X; Su D; Chen XC; Chen LJ; Wei YQ; Zhong Q; Li ZY; He X; Yi T
    Oncology; 2009; 77(1):22-32. PubMed ID: 19440000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.